{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-424739","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2026-10-19T13:00:13+00:00","discovered_at":"2026-10-19T13:01:02.052392+00:00","generated_at":"2026-10-19T13:01:14.121849+00:00","sec_items":["8.01"],"event_type":"litigation","sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"confidence":"high","headline":"Ultragenyx settles DOJOLVI patent suit with Navinta; generic entry set for Jan 1, 2033","bullets":["Settlement among Ultragenyx, Baylor Research Institute and Navinta LLC resolves ANDA patent litigation in the U.S. District Court for the District of New Jersey over DOJOLVI (triheptanoin).","Navinta receives a non-exclusive, royalty-free license to market its generic DOJOLVI beginning January 1, 2033, extending to July 1, 2033 if pediatric exclusivity is granted.","Litigation against other ANDA filers seeking generic DOJOLVI approval remains pending in the U.S. District Court for the District of New Jersey.","No financial terms or payments disclosed; the settlement will be submitted to the U.S. FTC and Department of Justice as required by law."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-424739","json":"https://secwatch.observer/filing/0001193125-26-424739.json","markdown":"https://secwatch.observer/filing/0001193125-26-424739.md","text":"https://secwatch.observer/filing/0001193125-26-424739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/0001193125-26-424739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000119312526424739/rare-20261019.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-19T13:01:14.121849+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}